Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.

Reule S, Pickthorn S, Drake T, Ishani A, Foley R.

Open source

DOI
10.1016/j.aed.2025.12.001
Published
2025-12-08
Container
AACE Endocrinol Diabetes
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.aed.2025.12.001,
  title = {Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.},
  author = {Reule S and  Pickthorn S and  Drake T and  Ishani A and  Foley R.},
  year = {2026},
  journal = {AACE Endocrinol Diabetes},
  doi = {10.1016/j.aed.2025.12.001},
  url = {https://doi.org/10.1016/j.aed.2025.12.001}
}

RIS

TY  - JOUR
TI  - Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.
AU  - Reule S
AU  -  Pickthorn S
AU  -  Drake T
AU  -  Ishani A
AU  -  Foley R.
PY  - 2026
JO  - AACE Endocrinol Diabetes
DO  - 10.1016/j.aed.2025.12.001
UR  - https://doi.org/10.1016/j.aed.2025.12.001
ER  - 

APA

S, R., S, P., T, D., A, I., & R., F. (2026). Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.. AACE Endocrinol Diabetes. https://doi.org/10.1016/j.aed.2025.12.001

Source records